Loading…
Nautilus Biotechnology, Inc. is projected to rise to $2.19 by 2027, a +15% move from its current price of $1.90. NAUT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.82 | $1.90 | $1.98 | +0.10% |
| Jul 13 | $1.79 | $1.90 | $2.02 | +0.19% |
| Jul 14 | $1.77 | $1.91 | $2.05 | +0.29% |
| Jul 15 | $1.75 | $1.91 | $2.08 | +0.38% |
| Jul 16 | $1.74 | $1.91 | $2.10 | +0.48% |
| Jul 17 | $1.72 | $1.91 | $2.12 | +0.57% |
| Jul 18 | $1.71 | $1.91 | $2.14 | +0.67% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.71 | $1.91 | $2.14 | +0.67% |
| Week 2 | $1.64 | $1.93 | $2.25 | +1.34% |
| Week 3 | $1.60 | $1.94 | $2.35 | +2.01% |
| Week 4 | $1.56 | $1.95 | $2.44 | +2.70% |
| Week 5 | $1.53 | $1.96 | $2.52 | +3.38% |
| Week 6 | $1.50 | $1.98 | $2.60 | +4.07% |
| Week 7 | $1.48 | $1.99 | $2.67 | +4.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nautilus Biotechnology, Inc. is a development stage life sciences company that engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The Nautilus Voyager Platform includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
It also provides the Nautilus Voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
The company has research collaboration agreements with Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
NAUT current price is $1.79 and has a market cap of $254.16M. The stock is ranked 5254 by market capitalization in the public markets.
The near-term price action is neutral, with a last price near the defined technicals. The 30-day range spans $1.32 to $2.43, while the stock trades with RSI14 at 30 and moving averages at $2.54 (SMA50) and $2.14 (SMA200). Support is listed at $1.79 and resistance at $2.77, highlighting a tight near-term band around a low-priced biotech name.
The forecast shows a path from a flat 2026 average ($1.79) toward stronger upside later in the horizon, with max forecasts climbing to $4.55 by 2032, $9.91 by 2040, and $16.02 by 2050. The 2026–2031 period is labeled NEUTRAL, then the outlook turns BULLISH into the later years with rising averages and larger upside potential. Annualized volatility is high at 90%, underscoring substantial near-term risk alongside longer-run upside.
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 11.1% below — buyers have tended to step in here.
The nearest ceiling, 45.8% above — a clean break opens room to run.
A major ceiling 107.9% above — clearing it would confirm fresh momentum.
Key NAUT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAUT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.80 | Buy | $1.84 | Buy |
| MA 10 | $1.82 | Buy | $1.89 | Buy |
| MA 20 | $2.04 | Sell | $2.02 | Sell |
| MA 50 | $2.39 | Sell | $2.29 | Sell |
| MA 100 | $2.64 | Sell | $2.37 | Sell |
| MA 200 | $2.18 | Sell | $2.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.58 | Neutral |
| Stoch RSI (14) | 65.14 | Neutral |
| CCI (20) | -46.06 | Neutral |
| Williams %R (14) | -70.15 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -18.88 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 29.85 | Neutral |
| TRIX (15) | -1.11 | Sell |
| Awesome (5,34) | -0.45 | Sell |
| Ultimate (7,14,28) | 43.71 | Neutral |
| Momentum (10) | -0.38 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.83 | Buy |
| ADX (14) | 25.50 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day technical picture places the price within a tight band around support and resistance. The 30-day range runs from $1.32 to $2.43, and the current price of $1.79 sits at the stated support level of $1.79.
RSI (14) is 30, suggesting proximity to oversold conditions, while the SMA50 at $2.54 sits above the current price and the SMA200 at $2.14 provides a longer-term anchor. The immediate resistance is $2.77, with a near-term risk/reward skew toward downside if the price breaks below support. The overall sentiment remains NEUTRAL, with substantial near-term volatility implied by the 90% annualized volatility figure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.69 | $1.90 | $2.86 | 0% | Neutral | |
| $1.65 | $2.19 | $3.11 | +15% | Neutral | |
| $1.54 | $2.14 | $3.21 | +13% | Neutral | |
| $1.66 | $2.39 | $3.73 | +26% | Bullish | |
| $1.48 | $2.20 | $3.55 | +16% | Neutral | |
| $1.53 | $2.35 | $3.91 | +24% | Bullish | |
| $1.93 | $3.07 | $5.23 | +61% | Bullish | |
| $2.06 | $3.36 | $5.87 | +77% | Bullish | |
| $2.29 | $3.83 | $6.85 | +102% | Bullish | |
| $2.19 | $3.77 | $6.86 | +98% | Bullish | |
| $2.93 | $5.72 | $11.32 | +201% | Bullish | |
| $4.02 | $8.94 | $19.89 | +371% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.69 | $1.90 | $2.39 | +0.00% |
| August 2026 | $1.74 | $2.08 | $2.58 | +9.53% |
| September 2026 | $1.71 | $2.07 | $2.61 | -0.44% |
| October 2026 | $1.70 | $2.08 | $2.66 | +0.45% |
| November 2026 | $1.77 | $2.18 | $2.82 | +4.79% |
| December 2026 | $1.76 | $2.19 | $2.86 | +0.34% |
Click any year to see its month-by-month NAUT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NAUT is projected to trade between $1.69 and $2.86, averaging $1.90 — a potential gain of 0% from today's $1.90. A consolidation phase looks the most probable path here.
Nautilus Biotechnology, Inc.'s 2027 outlook centres on $2.19, within a $1.65 to $3.11 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2028, NAUT could reach as high as $3.21, with a base case around $2.14 and support toward $1.54 — roughly +13% from $1.90. A consolidation phase looks the most probable path here.
Expect NAUT to range from $1.66 to $3.73 through 2029. The $2.39 average target implies a +26% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The NAUT price prediction for 2030 points to an average of $2.20 (low $1.48, high $3.55) — a potential gain of +16% on today's $1.90. A consolidation phase looks the most probable path here.
In 2031, NAUT is projected to trade between $1.53 and $3.91, averaging $2.35 — a potential gain of +24% from today's $1.90. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Nautilus Biotechnology, Inc.'s 2032 outlook centres on $3.07, within a $1.93 to $5.23 range. That is up +30% on the projected 2031 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, NAUT could reach as high as $5.87, with a base case around $3.36 and support toward $2.06 — roughly +77% from $1.90. Momentum favours further upside here.
Expect NAUT to range from $2.29 to $6.85 through 2034. The $3.83 average target implies a +102% move from current prices. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NAUT price prediction for 2035 points to an average of $3.77 (low $2.19, high $6.86) — a potential gain of +98% on today's $1.90. Momentum favours further upside here.
In 2040, NAUT is projected to trade between $2.93 and $11.32, averaging $5.72 — a potential gain of +201% from today's $1.90. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Nautilus Biotechnology, Inc.'s 2050 outlook centres on $8.94, within a $4.02 to $19.89 range. That is up +56% on the projected 2040 average. That marks a +371% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NAUT today (≈ 526.315789 NAUT) could be worth
$4,706.97
+$3,706.97 (+371%) by 2050 · US Dollar
Based on the average projected NAUT price of $8.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAUTwould be worth at today's price.
$1,000 invested in NAUT on Jul 10, 2025 (≈ 1,329.78728 NAUT) would be worth
$2,526.6
+$1,526.6 (+152.7%) today · 2.53× · US Dollar
Based on a NAUT entry price of $0.752 vs. today's $1.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.73 | $1,098.27 | +9.8% |
| 1 month ago | $2.26 | $840.71 | -15.9% |
| 3 months ago | $2.95 | $644.07 | -35.6% |
| 6 months ago | $1.99 | $954.77 | -4.5% |
| 1 year ago | $0.752 | $2,526.6 | +152.7% |
| All time (5.0y) ago | $10 | $190 | -81.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAUT forecast.
Our base-case forecast reaches $3.80 around 2034.
Implied market cap at $3.80: $482.9M
Looking further out, the multi-year forecast shows meaningful upside beginning in 2032 and beyond. In 2032 the min is $1.56, the avg $2.58, the max $4.55, with a 44% ROI and a BULLISH tone, followed by 2033 with min $1.71, avg $2.92, max $5.28 and a 63% ROI in a bullish context. 2034 projects min $1.89, avg $3.34, max $6.18 with an 86.4% ROI, and 2035 shows min $1.74, avg $3.16, max $5.98 with a 76.6% ROI, all continuing under a BULLISH sentiment.
By 2040, the forecast expands to a min of $2.28, an avg of $4.80, and a max of $9.91, with a 168.3% ROI and a clearly BULLISH outlook. By 2050, the min is $3.13, the avg is $6.97, and the max is $16.02, representing a 289.1% ROI and continued BULLISH sentiment. These figures illustrate a trajectory from flat near-term prospects to substantial longer-term upside, acknowledging that actual results can differ from projections and that higher volatility remains a risk in this space.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $1.94 with a min of $1.26 and a max of $3.23; ROI 8.6%.
The near-term is NEUTRAL with a run of forecasts from 2026–2031. From 2032 onward, the outlook becomes BULLISH with a 44% ROI in 2032 and rising to 289.1% by 2050, according to the forecast.
The forecast max in 2040 is $9.91, which is below $10. By 2050 the max is $16.02, which exceeds $10.
Current price is $1.79 and market cap is $254.16M.
RSI (14) is 30, indicating neutral/oversold conditions. SMA50 is $2.54 and SMA200 is $2.14. The 30-day range is $1.32 to $2.43, with support at $1.79 and resistance at $2.77, and sentiment remains NEUTRAL.
Nautilus Biotechnology, Inc. Community Discussion
0Share your Nautilus Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.